Comparative evaluation of two fixed doses of 185 and 370 MBq 131I, for the treatment of Graves' disease resistant to antithyroid drugs

Hellenic Journal of Nuclear Medicine

Volumn 8, Issue 3, 2005, Pages 158-161

  Esfahani, Armaghan Fard ^a   Kakhki, Vahid R Dabbagh ^a   Fallahi, Babak ^a   Eftekhari, Mohammad ^a   Beiki, Davood ^a   Saghari, Mohsen ^a   Takavar, Abbas ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

131I dose evaluation; 131I treatment; Fixed 131I dose; Graves' disease; High 131I dose; Low 131I dose

Indexed keywords

ANTITHYROID AGENT; IODINE 131; LIOTHYRONINE; THYROTROPIN; THYROXINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; COST EFFECTIVENESS ANALYSIS; EUTHYROIDISM; FEMALE; FOLLOW UP; FREE LIOTHYRONINE INDEX; FREE THYROXINE INDEX; GRAVES DISEASE; HEALTH CARE COST; HUMAN; HYPOTHYROIDISM; INCIDENCE; IODINE 131 UPTAKE TEST; IRAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OPTIMAL DRUG DOSE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; THYROID FUNCTION TEST; THYROID GLAND; THYROTROPIN BLOOD LEVEL; TREATMENT FAILURE; TREATMENT OUTCOME; TURNOVER TIME;

ADULT; AGE DISTRIBUTION; AGED; ANTITHYROID AGENTS; DOSE-RESPONSE RELATIONSHIP, RADIATION; DRUG RESISTANCE; FEMALE; GRAVES DISEASE; HUMANS; IODINE RADIOISOTOPES; IRAN; MALE; MIDDLE AGED; PROGNOSIS; RADIOPHARMACEUTICALS; RISK ASSESSMENT; RISK FACTORS; SEX DISTRIBUTION; TREATMENT OUTCOME;

EID: 30344472679     PISSN: 17905427     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Bender JM. Dworkin HJ. Therapy of hyperthyroidism. In: Henkin RE, Boles MA, Karesh SM, et al. Nuclear Medicine. Mosby St. Louis 1996; 1549-1556.
2. Becker DV, Hurnley JR. Radioidine treatment of hyperthyriodism. In: Sandler MP, Patton JA, Gottschalk A. Diagnostic Nuclear Medicine. Wiliams & Wilkims. Pennsylvania 1996; 943-955.
3. 131I therapy for Graves'disease. Eur J Nucl Med Mol Imaging Epub 2002; 29 Suppl 2: S453-457.
4. 131I therapy of the thyroid. In: Murray IPC, Ell PJ, van der Wall H, Strauss HW. Nuclear medicine in clinical diagnosis and treatment Churchill Livingstone. Hong Kong 1998; 1049-1062.
5. 131I therapy in immune hyperthyroidism. Acta Med Austriaca 1987; 14: 99-101.
6. 131I) treatment of hyperthyroidism. In: Freeman LM, Wesiman HS. Nuclear Medicine Annual. Raven press. New York 1982; 265-290.
7. Soloman DH. Radioiodine. Iodine-131, In: Ingbar SH, Broverman LE. The Thyroid. Lippincott, Philadelphia 1986; 1001-1003.
8. Kusakabe K, Maki M. Radioactive iodine (I-131) therapy. Nippon Rinsho 1999; 57: 1855-1858.
9. 131I doses in Graves' hyperthyroidism. J Clin Endocrinol Metab 2003; 88: 978-983.
10. Doi SA, Loutfi I, Al-Shoumer KA. A mathematical model of optimized radioiodine-131 therapy of Graves' hyperthyroidism. BMC Nucl Med Epub 2001; 1: 1.
11. Nebesio TD, Siddiqui AR, Pescovitz OH, Eugster EA. Time course to hypothyroidism after fixed-dose radioablation therapy of Graves' disease in children. J Pediatr 2002; 141: 99-103.
12. 131I treatment of hyperthyroidism-prognostic factors for outcome. J Clin Endocrinol Metab 2001; 86: 3611-3617.
13. Danaci M, Feek CM, Notghi A, et al. Radioiodine-131 therapy for hyperthyroidism in patients with Graves' disease, uninodular goitre and multinodular goitre. New Zeal Med J 1988; 101: 784-786.
14. Nordyke RA, Gilbert FI. Optimal iodine-131 dose for eliminating hyperthyroidism in Graves' disease. J Nucl Med 1991; 32: 411-416.
15. Sankar R, Sripathy G. Radioactive iodine therapy in Graves' hyperthyroidism. Natl Med J India 2000; 13: 246-251.
16. 131I therapy for hyperthyroidism: Long term follow up study. Brit Med J 1984; 289: 361-363.